William Blair Brokers Lower Earnings Estimates for Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at William Blair lowered their FY2024 EPS estimates for Zevra Therapeutics in a research report issued on Wednesday, September 18th. William Blair analyst S. Corwin now expects that the company will earn ($1.60) per share for the year, down from their previous estimate of ($1.58). William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.58) per share. William Blair also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at $0.28 EPS, Q2 2025 earnings at $0.18 EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.03 EPS and FY2025 earnings at $0.60 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same quarter last year, the business earned ($0.15) earnings per share.

A number of other equities research analysts have also recently commented on ZVRA. Cantor Fitzgerald reiterated an “overweight” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 14th. HC Wainwright increased their price objective on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Friday. Finally, Canaccord Genuity Group lowered their target price on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Wednesday. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Zevra Therapeutics currently has an average rating of “Buy” and a consensus price target of $21.25.

Zevra Therapeutics Stock Up 0.5 %

Zevra Therapeutics stock opened at $8.06 on Friday. Zevra Therapeutics has a 1-year low of $3.89 and a 1-year high of $8.95. The business has a fifty day moving average price of $7.04 and a 200-day moving average price of $5.71. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.00 and a quick ratio of 2.00. The stock has a market capitalization of $337.34 million, a price-to-earnings ratio of -5.97 and a beta of 1.94.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director Thomas Anderson acquired 10,000 shares of Zevra Therapeutics stock in a transaction dated Tuesday, July 16th. The stock was purchased at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the completion of the purchase, the director now directly owns 20,000 shares in the company, valued at approximately $136,200. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have bought 22,000 shares of company stock worth $140,340. 2.40% of the stock is currently owned by insiders.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ZVRA. Jump Financial LLC purchased a new stake in Zevra Therapeutics in the fourth quarter valued at $217,000. Focus Financial Network Inc. ADV purchased a new position in shares of Zevra Therapeutics during the 4th quarter valued at about $141,000. Armistice Capital LLC acquired a new position in shares of Zevra Therapeutics in the 4th quarter valued at about $1,755,000. Virtu Financial LLC purchased a new stake in shares of Zevra Therapeutics in the fourth quarter worth about $177,000. Finally, IFG Advisors LLC grew its holdings in Zevra Therapeutics by 45.0% during the first quarter. IFG Advisors LLC now owns 18,700 shares of the company’s stock worth $108,000 after acquiring an additional 5,800 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.